Sun Pharma ends development of SCD-044 after phase 2 trials fail to meet primary endpoints EP News Bureau Jun 4, 2025 SCD-044 trials for psoriasis and atopic dermatitis show no major safety concerns
Sun Pharma starts Phase II trial of SCD-044 for moderate to severe plaque psoriasis EP News Bureau Jan 4, 2021 SCD-044 is also being evaluated in other autoimmune disorders and Phase 2 studies for other indications like atopic dermatitis,…
SPARC and Sun Pharma enter into license agreement for SCD-044 EP News Bureau May 29, 2020 It is a potential treatment for atopic dermatitis, psoriasis and other auto-immune disorders
